JC17 Rec'd PCT/AGG 17 JUN 2005

In the Claims:

Claims 1-99 (Canceled).

- 100. (New) A method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.
- 101. (New) The method of claim 100, wherein said compound is selected from the group consisting of:
 - (a) a molecule capable of binding said AMP and/or AMP-like molecule;
 - (b) an enzyme capable of cleaving said AMP and/or AMP-like molecule;
 - (c) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule;
 - (d) a DNAzyme capable of cleaving an mRNA or DNA encoding said AMP and/or AMP-like molecule;
 - (e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule;
 - (f) a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule;
 - (g) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule;
 - (h) a molecule capable of inhibiting activation or ligand binding of said
 AMP and/or AMP-like molecule; and
 - (i) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.
- 102. (New) The method of claim 101, wherein said molecule capable of binding said AMP and/or AMP-like molecule is an antibody or an antibody fragment.

- 103. (New) The method of claim 100, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 104. (New) The method of claim 100, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.
- 105. (New) The method of claim 100, wherein the disease is selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, and an endothelial disease.
- 106. (New) An article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease being associated with a biological process in a cell and/or tissue, the biological process being selected from the group consisting of growth, differentiation, inflammation, metastasis and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule.
- 107. (New) The article of manufacture of claim 106, wherein said compound is selected from the group consisting of:
 - (a) a molecule capable of binding said AMP and/or AMP-like molecule;
 - (b) an enzyme capable of cleaving said AMP and/or AMP-like molecule;
 - (c) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule;
 - (d) a DNAzyme capable of cleaving an mRNA or DNA encoding said
 AMP and/or AMP-like molecule;
 - (e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule;
 - a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule;
 - (g) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule; and

- (h) a molecule capable of inhibiting activation or ligand binding of said

 AMP and/or AMP-like molecule; and
- (i) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.
- 108. (New) The article of manufacture of claim 107, wherein said molecule capable of binding said AMP is an antibody or an antibody fragment.
- 109. (New) The article of manufacture of claim 106, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 110. (New) The article of manufacture of claim 106, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.
- 111. (New) The article of manufacture of claim 106, wherein said disease is selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, an endothelial disease and a human disease.
- 112. (New) The article of manufacture of claim 106, wherein said disease is psoriasis or skin carcinoma.
- 113. (New) A method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.
- 114. (New) The method of claim 113, wherein said providing to the subject said AMP and/or AMP-like molecule is effected by administering said AMP and/or AMP-like molecule to the subject and/or by expressing said AMP and/or AMP-like molecule in the subject.

- 115. (New) The method of claim 113, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 116. (New) The method of claim 113, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1, beta-defensin-2 and LL-37.
- 117. (New) The method of claim 113, wherein the disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.
- 118. (New) An article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease being associated with a biological process in a cell and/or tissue, said biological process being selected from the group consisting of growth, differentiation, inflammation and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an antimicrobial peptide (AMP) and/or AMP-like molecule.
- 119. (New) The article of manufacture of claim 118, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 120. (New) The article of manufacture of claim 118, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.
- 121. (New) The article of manufacture of claim 118, wherein said disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.